Skip to content
value.today

Cherrypharm Inc.

Total raised
$50 M
8 rounds on record
Latest round
$21 M
Oct 2019
First round on record
Aug 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Cherrypharm Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2019$21 MNo. 8$10 to $50 million

Cherrypharm Inc.: Raise no. 8, Oct 2019

Investors in this round

3 investors had bought by the notice of Jun 26, 2020: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$21 M of $32 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$175,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ben Fineberg · Executive Officer
  • Mike Hagan · Executive Officer
  • Andreas Guldin · Director
  • Marcel Bens · Director
  • Morgan Ratcliffe · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mike Hagan, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 26, 2020. Read the notice at the SEC.

equity, optionsSEC
Mar 2018$10 MNo. 7$10 to $50 million

Cherrypharm Inc.: Raise no. 7, Mar 2018

Investors in this round

43 investors had bought by the notice of Aug 9, 2018: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $17 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Brophy · Executive Officer
  • Mike Hagan · Executive Officer
  • Steven Pear · Executive Officer, Director
  • Andreas Guldin · Director
  • John Shields · Director
  • Michael Oringer · Director
  • Scott Roman · Director
  • Thomas Facer · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Pear, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 9, 2018. Read the notice at the SEC.

debt, optionsSEC
Mar 2018$5 MNo. 6$2 to $10 million

Cherrypharm Inc.: Raise no. 6, Mar 2018

Investors in this round

11 investors had bought by the notice of Mar 20, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bill Brophy · Executive Officer
  • Mike Hagan · Executive Officer
  • Steven Pear · Executive Officer, Director
  • Andreas Guldin · Director
  • John Shields · Director
  • Michael Oringer · Director
  • Scott Roman · Director
  • Thomas Facer · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Pear, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 20, 2018. Read the notice at the SEC.

debt, optionsSEC
Mar 2016$5 MNo. 5$2 to $10 million

Cherrypharm Inc.: Raise no. 5, Mar 2016

Investors in this round

12 investors had bought by the notice of Nov 2, 2017: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • James O'Callaghan · Executive Officer
  • Mike Hagan · Executive Officer
  • Stephen Pear · Executive Officer, Director
  • Andreas Guldin · Director
  • Hans Heer · Director
  • John Shields · Director
  • Michael Oringer · Director
  • Thomas Facer · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Pear, Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Nov 2, 2017. Read the notice at the SEC.

equity, optionsSEC
Nov 2014$2 MNo. 4Under $2 million

Cherrypharm Inc.: Raise no. 4, Nov 2014

Investors in this round

2 investors had bought by the notice of Dec 3, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edmund Maguire · Executive Officer
  • Stephen Pear · Executive Officer, Director
  • Andreas Guldin · Director
  • Hans Heer · Director
  • John Shields · Director
  • Michael Oringer · Director
  • Thomas Facer · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Edmund Maguire, Vice President and Secretary. Source: SEC Form D, newest notice filed Dec 3, 2014. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$1 MNo. 3Under $2 million

Cherrypharm Inc.: Raise no. 3, Nov 2013

Investors in this round

5 investors had bought by the notice of Apr 2, 2014: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$10,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Ross · Executive Officer, Director, Promoter
  • Edmund Maguire · Executive Officer
  • Andreas Guldin · Director
  • Hans Heer · Director
  • John Shields · Director
  • Michael Oringer · Director
  • Thomas Facer · Director
  • Zachary Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Edmund Maguire, Vice President and Secretary. Source: SEC Form D, newest notice filed Apr 2, 2014. Read the notice at the SEC.

debt, optionsSEC
Feb 2012$5 MNo. 2$2 to $10 million

Cherrypharm Inc.: Raise no. 2, Feb 2012

Investors in this round

32 investors had bought by the notice of Feb 21, 2012: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian Ross · Executive Officer, Director
  • Brittany Ridley · Executive Officer
  • Andreas J. Guldin · Director
  • John Shields · Director
  • Thomas J. Facer · Director
  • William J. Weiland · Director
  • Zachary J. Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Ross, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 21, 2012. Read the notice at the SEC.

equitySEC
Aug 2009$2 MNo. 1Under $2 million

Cherrypharm Inc.: Raise no. 1, Aug 2009

Investors in this round

32 investors had bought by the notice of Jan 21, 2010: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carol P. Langdon · Executive Officer · Treasurer and Secretary
  • Donald S. Copland · Director, Executive Officer · President and Chief Executive Officer
  • Christopher L. Shoemaker · Director
  • Thomas A. Facer · Director
  • Thomas P. Burnet · Director
  • Zachary L. Shulman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering closed in December 2009 - no further amount will be sold.”
  • On the use of proceeds: “$50,000 of proceeds were paid to a former director at the time of the initial offering and who has since resigned as a director.”

Signed by Donald S. Copland, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 21, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cherrypharm Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2020).

    SEC Form D · Jun 2020

  • The industry group it chose in its notices: Other.

    SEC Form D · Jun 2020

That is all the official record says: Cherrypharm Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Cherrypharm Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cherrypharm Inc.
NameRoleNamed in
Ben FinebergExecutive officerJun 2020
Mike HaganExecutive officerJun 2020
Bill BrophyExecutive officerOct 2019
Steven PearExecutive officerAug 2018
James O'CallaghanExecutive officerNov 2017
Stephen PearExecutive officerNov 2017
Edmund J. MaguireExecutive officerMar 2016
James J. O'CallaghanExecutive officerMar 2016
Mike J. HaganExecutive officerMar 2016
Edmund MaguireExecutive officerDec 2014
Brian RossExecutive officerApr 2014
Brittany RidleyExecutive officerFeb 2012
Carol P. LangdonTreasurer and SecretaryJan 2010
Donald S. CoplandPresident and Chief Executive OfficerJan 2010
Andreas GuldinDirectorJun 2020
Marcel BensDirectorJun 2020
Morgan RatcliffeDirectorJun 2020
Zachary ShulmanDirectorJun 2020
Bill BrophyDirectorOct 2019
John ShieldsDirectorOct 2019
Michael OringerDirectorOct 2019
Scott RomanDirectorOct 2019
Thomas FacerDirectorOct 2019
Steven PearDirectorAug 2018
Hans HeerDirectorNov 2017
Stephen PearDirectorNov 2017
Brian RossDirectorApr 2014
Andreas J. GuldinDirectorFeb 2012
Thomas J. FacerDirectorFeb 2012
William J. WeilandDirectorFeb 2012
Zachary J. ShulmanDirectorFeb 2012
Christopher L. ShoemakerDirectorJan 2010
Donald S. CoplandPresident and Chief Executive OfficerJan 2010
Thomas A. FacerDirectorJan 2010
Thomas P. BurnetDirectorJan 2010
Zachary L. ShulmanDirectorJan 2010
Brian RossPromoterApr 2014